Mostrar el registro sencillo del ítem
dc.contributor.author
Arrieta, O.
dc.contributor.author
Mascheroni, M. B.
dc.contributor.author
Recondo, Gonzalo
dc.contributor.author
Kaen, D
dc.contributor.author
Zhang, J.
dc.contributor.author
Patel, D.
dc.contributor.author
Swallow, E.
dc.contributor.author
Balu, S
dc.contributor.author
Camacho, O. C.
dc.contributor.author
Ratto, B
dc.contributor.author
Kageleiry, A
dc.contributor.author
Stein, K
dc.contributor.author
Degun, R
dc.contributor.author
Martin, C
dc.date.available
2019-02-19T18:13:30Z
dc.date.issued
2015-11
dc.identifier.citation
Arrieta, O.; Mascheroni, M. B.; Recondo, Gonzalo; Kaen, D; Zhang, J.; et al.; Real-World Patient Characteristics, Treatment Patterns, and Survival among Locally-Advanced/Metastatic Alk+ Non-Small Cell Lung Cancer Patients in Latin America; Wiley Blackwell Publishing, Inc; Value In Health; 18; 7; 11-2015
dc.identifier.issn
1098-3015
dc.identifier.uri
http://hdl.handle.net/11336/70461
dc.description.abstract
Objectives To describe patient characteristics, treatment patterns, and survival among Latin American patients diagnosed with locally-advanced/metastatic ALK+ non-small cell lung cancer (NSCLC). Methods Mexican and Argentine oncologists (N=5) reviewed patient charts and reported characteristics, treatment patterns, and survival on their patients diagnosed with ALK+ locally-advanced/metastatic NSCLC. Treatment duration and overall survival (OS) were estimated using Kaplan-Meier analyses. Results Patients (N=25) averaged 57 years old when diagnosed with locally-advanced/metastatic NSCLC; 64% were female, 56% were Hispanic, 44% were Caucasian, 48% were uninsured, and 24% were unemployed or on sick leave. Smoking history varied (36% never-smokers, 20% light/moderate smokers, and 32% heavy smokers). At primary diagnosis, 72% had metastatic disease. Over the course of their disease (until end of follow-up), 48% of patients developed brain metastases, 20% bone, and 32% lung. In first-line therapy, 17 patients (68%) received chemotherapy and six patients (24%) received crizotinib. After first-line chemotherapy, six patients (24%) received crizotinib. 13 patients (52%) never received an ALK inhibitor; of these, nine patients (69%) did not receive crizotinib because they could not afford it or crizotinib was not covered by insurance. Out of the 12 patients who received crizotinib, three died, and eight discontinued by the end of follow-up (median duration of 127 days), with three patients switching to chemotherapy, one to afatinib, and four receiving no further antineoplastic therapy. After diagnosis of locally-advanced/metastatic NSCLC, the OS rate among all patients was 74% at 12 months. Conclusions Though the sample size is small, the study provides the first analysis of patient characteristics, treatment patterns, and survival among ALK+ NSCLC patients in Latin America. Many patients were women, uninsured, never received an ALK inhibitor, and their OS was low. These findings suggest that there could be an unmet need for access to effective treatments for ALK+ NSCLC patients in Latin America.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Wiley Blackwell Publishing, Inc
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Non Small Cell Lung Cancer
dc.subject
Latin America
dc.subject.classification
Medicina Critica y de Emergencia
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Real-World Patient Characteristics, Treatment Patterns, and Survival among Locally-Advanced/Metastatic Alk+ Non-Small Cell Lung Cancer Patients in Latin America
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-02-19T15:11:13Z
dc.journal.volume
18
dc.journal.number
7
dc.journal.pais
Reino Unido
dc.journal.ciudad
Londres
dc.description.fil
Fil: Arrieta, O.. Instituto Nacional de Cancerologia; Macao
dc.description.fil
Fil: Mascheroni, M. B.. Sanatorio Nosiglia; Argentina
dc.description.fil
Fil: Recondo, Gonzalo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET.; Argentina
dc.description.fil
Fil: Kaen, D. Centro Oncologico Riojano Integral; Argentina
dc.description.fil
Fil: Zhang, J.. Novartis Pharmaceuticals Corporation; Estados Unidos
dc.description.fil
Fil: Patel, D.. Navigant Consulting; Estados Unidos
dc.description.fil
Fil: Swallow, E.. Analysis Group; Estados Unidos
dc.description.fil
Fil: Balu, S. Novartis Pharmaceuticals Corporation; Estados Unidos
dc.description.fil
Fil: Camacho, O. C.. Novartis Farmaceutica; Estados Unidos
dc.description.fil
Fil: Ratto, B. Novartis Argentina S.A; Argentina
dc.description.fil
Fil: Kageleiry, A. Analysis Group; Estados Unidos
dc.description.fil
Fil: Stein, K. Novartis Pharmaceuticals Corporation; Estados Unidos
dc.description.fil
Fil: Degun, R. Navigant Consulting Inc.; Reino Unido
dc.description.fil
Fil: Martin, C. Fleming Institute; Argentina
dc.journal.title
Value In Health
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://linkinghub.elsevier.com/retrieve/pii/S109830151502313X
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.1016/j.jval.2015.09.237
Archivos asociados